On December 17, 2025, VYNE Therapeutics Inc. entered into a merger agreement with Yarrow Bioscience, where Yarrow will become a wholly owned subsidiary of VYNE, expecting Yarrow shareholders to own approximately 97% of the combined company post-merger. The transaction includes a pre-closing dividend of around $14.5-16.5 million to pre-merger VYNE shareholders and is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals.